Drugs / Admilparant
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 116 trials | ||||||
| Phase 1 | NCT07422298 | Feb → Jun 2026 overdue | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1 | NCT07225647 | Nov 2025 → Jan 2026 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT06746402 | Feb → Sep 2025 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT06715683 | Dec 2024 → Mar 2025 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT06723535 | Dec 2024 → Sep 2025 | chronic renal failure syndrome, impaired renal function disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT06568458 | Sep 2024 → Feb 2025 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT06425198 | Jun → Dec 2024 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05985590 | Aug → Dec 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05932303 | Jul → Oct 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05805904 | Mar → May 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05684289 | Jan → May 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04567667 | Oct 2020 → Apr 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04468815 | Jul → Oct 2020 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03981094 | May → Jul 2019 | idiopathic pulmonary fibrosis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03712540 | Sep → Nov 2018 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03429933 | Feb 2018 → Mar 2019 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04308681 | Jul 2020 → Aug 2022 | pulmonary fibrosis | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT07441408 | Dec 2026 → Nov 2029 expected | pulmonary fibrosis | Bristol-Myers Squibb | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06025578 | Oct 2023 → Dec 2027 expected | pulmonary fibrosis | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06003426 | Sep 2023 → Oct 2026 expected | idiopathic pulmonary fibrosis | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-10-24 | Bristol-Myers Squibb | Regulatory Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis bms.com ↗
the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for BMS-986278 |
| 2023-09-09 | Bristol-Myers Squibb | Results Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study bms.com ↗ |
| 2023-05-22 | Bristol-Myers Squibb | Results Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis bms.com ↗
The study showed twice-daily administration of 60 mg of BMS-986278 over 26 weeks reduced the rate of decline in percent predicted forced vital capacity (ppFVC) by 62% compared to placebo. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-10-24 | Bristol-Myers Squibb | Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis bms.com ↗ |
| 2023-09-09 | Bristol-Myers Squibb | Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study bms.com ↗ |
| 2023-05-22 | Bristol-Myers Squibb | Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis bms.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | admilparant | “Admilparant (BMS-986278) is an oral lysophosphatidic acid receptor 1 antagonist under development for treatment of IPF and PPF.” PMID 40210090 ↗ Apr 2025 |
| Known as | BMS-986278 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05684289 ↗ |
| Action | Inhibit | “is a potent lysophosphatidic acid receptor 1 (LPA1) antagonist” PMID 34709814 ↗ Oct 2021 |
| Modality | Small molecule | — CHEMBL5087506 ↗ |
| Route | Oral | “Oral administration 30 mg” NCT03712540 ↗ |